All Comments by David Holtzman
- In Familial AD, Amyloid-PET Varies by Mutation Type; CSF Aβ42 Doesn't
- CMS Plans to Limit Aduhelm Coverage to Clinical Trials
- Plasma Aβ—First Sign of AD, But Tough to Measure Prospectively?
- What FDG PET ‘Sees’ in AD: Angry Microglia, Not Just Neurons
- Protective APOE3 Variant Binds More Lipids, Self-Aggregates Less
- PET Firms Up Amyloid Cascade: Plaques, Inflammation, Tangles
- Aducanumab Approved to Treat Alzheimer’s Disease
- Forget Typical Alzheimer's: AI Finds Four Types.
- Aducanumab Still Needs to Prove Itself, Researchers Say
- In Colombian Alzheimer’s Kindred, Blood NfL Climbs 22 Years Before Symptoms
- China Approves Seaweed Sugar as First New Alzheimer’s Drug in 17 Years
- Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report.
- ApoE4 and Tau in Alzheimer’s: Worse Than We Thought? Especially in Women
- Biogen/Eisai Halt Phase 3 Aducanumab Trials
- Rocking Improves Sleep and Memory in Adults